These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9865288)

  • 1. Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients.
    Seydoux C; Stumpe F; Hurni M; Ruchat P; Fischer A; Mueller X; von Segesser L; Goy JJ
    Transplant Proc; 1998 Dec; 30(8):4037-43. PubMed ID: 9865288
    [No Abstract]   [Full Text] [Related]  

  • 2. Does early steroid withdrawal influence rejection and infection episodes during the first 2 years after heart transplantation?
    Seydoux C; Berguer DG; Stumpe F; Hurni M; Ruchat P; Fischer A; Müller X; Sadeghi H; Goy JJ
    Transplant Proc; 1997; 29(1-2):620-4. PubMed ID: 9123157
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.
    Adamson R; Obispo E; Dychter S; Dembitsky W; Moreno-Cabral R; Jaski B; Gordon J; Hoagland P; Moore K; King J; Andrews J; Rich M; Daily PO
    Transplant Proc; 1998 Jun; 30(4):1107-9. PubMed ID: 9636449
    [No Abstract]   [Full Text] [Related]  

  • 4. Early cyclosporine blood levels impact the incidence of acute rejection and overall mortality in the first year after heart transplantation.
    Gómez-Sánchez MA; Delgado JF; Escribano P; Santos M; Sotelo T; Gil R; Hernández-Afonso J; Ortuño B; Romero F; Sáenz de la Calzada C; Rodriguez JE; Rufilanchas JJ
    Transplant Proc; 1998 Aug; 30(5):1671-2. PubMed ID: 9723237
    [No Abstract]   [Full Text] [Related]  

  • 5. Sole immunosuppressive maintenance with cyclosporine A after heart transplantation.
    Koerner MM; Tenderich G; Mannebach H; zu Knyphausen E; Koertke H; Kleesiek K; Gleichmann U; Meyer H; Koerfer R
    Transplant Proc; 1996 Dec; 28(6):3119-21. PubMed ID: 8962209
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A.
    Behr TM; Richter K; Fischer P; Spes CH; Meiser B; Reichart B; Pongratz D; Feucht H; Theisen K; Angermann CE
    Transplant Proc; 1998 Aug; 30(5):1920-1. PubMed ID: 9723333
    [No Abstract]   [Full Text] [Related]  

  • 7. Risks and benefits of withdrawing cyclosporine from the long-term immunosuppression regimen of heart and heart-lung transplant recipients.
    Walker S; Habib S; Thompson D; Khaghani A; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1149-51. PubMed ID: 9636465
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation.
    Maccherini M; Bernazzali S; Diciolla F; Giunti G; Bizzarri F; Lisi GF; Davoli G; Biagioli B; Giomarelli PP; Simeone F; Caciorgna M; Marchetti L; Pula G; Sani G; Toscano M
    Transplant Proc; 1998 Aug; 30(5):1904-5. PubMed ID: 9723327
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduction of early rejection in adult liver transplantation with ATG induction therapy.
    Schulak J; May E; Post A; Fasola C; Mulligan D; Sterling R
    Transplant Proc; 1997; 29(1-2):555-6. PubMed ID: 9123126
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine-based steroid-free therapy in pediatric heart transplantation: long-term results.
    Livi U; Caforio AL; Gambino A; Tursi V; Milanesi O; Stellin G; Angelini A; Casarotto D
    Transplant Proc; 1998 Aug; 30(5):1975-6. PubMed ID: 9723358
    [No Abstract]   [Full Text] [Related]  

  • 11. Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine.
    Sgrosso JL; Ferrer J; Araujo G; Romeo L; Parisi C; Vázquez MC
    Transplant Proc; 2002 Feb; 34(1):115-6. PubMed ID: 11959214
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction therapy with cyclosporine and without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients.
    Jazzar A; Fagiuoli S; Sisson S; Zuhdi N; Cooper DK
    Transplant Proc; 1994 Oct; 26(5):2749. PubMed ID: 7940864
    [No Abstract]   [Full Text] [Related]  

  • 13. Conversion from regular cyclosporine to microemulsion cyclosporine following heart transplantation.
    Heroux AL; LeBlanc MH; Beaudoin D; Simard S; Coulombe DA; Gleeton O; Lemieux MD; Doyle DP
    Transplant Proc; 1996 Dec; 28(6):3145-8. PubMed ID: 8962219
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclosporine heart transplantation.
    Cheung A; Menkis AH
    Transplant Proc; 1998 Aug; 30(5):1881-4. PubMed ID: 9723320
    [No Abstract]   [Full Text] [Related]  

  • 15. Morbidity, mortality beyond the 10th year following heart transplant: data from a population of 163 patients.
    Sebbag L; Boissonnat P; Obadia JF; Gare JP; Perinetti M; Loire R; Dureau G
    Transplant Proc; 2001; 33(7-8):3551-2. PubMed ID: 11750511
    [No Abstract]   [Full Text] [Related]  

  • 16. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
    Marcus N; Khaghani A; Burke M; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460
    [No Abstract]   [Full Text] [Related]  

  • 17. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
    Kobashigawa J; David K; Morris J; Chu AH; Steffen BJ; Gotz VP; Gordon RD
    Transplant Proc; 2005 Mar; 37(2):1333-9. PubMed ID: 15848713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term use of cyclosporine in cardiac transplantation: the Pitié experience.
    Dorent R; Tezenas S; Ghossoub JJ; Leger P; Lendvai N; Vaissier E; Levasseur JP; Eslami M; Pavie A; Gandjbakhch I
    Transplant Proc; 2002 May; 34(3):831-3. PubMed ID: 12034199
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients.
    Lietz K; John R; Schuster M; Ankersmit J; Burke E; Suciu-Foca N; Edwards N; Mancini D; Itescu S
    Transplant Proc; 2002 Aug; 34(5):1828-9. PubMed ID: 12176593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.